Cholesteryl Hemisuccinate (Synonyms: Cholesteryl hydrogen succinate) |
カタログ番号GC43258
One-Click Copy Product Info
|
Cholesteryl Hemisuccinateは酸性コレステロールエステルであり、肝臓保護と抗癌活性を持つ。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1510-21-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Cholesteryl Hemisuccinateは酸性コレステロールエステルであり、肝臓保護と抗癌活性を持つ[1, 2]。Cholesteryl HemisuccinateはDNAポリメラーゼとDNAトポイソメラーゼを阻害し、DNAの複製と修復を促進する[3]。Cholesteryl Hemisuccinateはタンパク質の結晶学、タンパク質生物化学研究と薬理学に広く使われた洗浄剤である[4]。Cholesteryl Hemisuccinateは上皮細胞の付着と拡散を阻害できる[5]。
生体内では、アセトアミノフェン（AAP）を投与されたICRマウスにCholesteryl Hemisuccinate (100mg/kg)を腹腔内投与で事前処理した結果、AAP誘発の肝損傷を阻害し、肝細胞壊死とアポトーシスを抑制した[6]。
References:
[1] Fariss M W, Fortuna M B, Everett C K, et al. The selective antiproliferative effects of α-tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds[J]. Cancer Research, 1994, 54(13): 3346-3351.
[2] Shah H, Madni A, Khan M M, et al. pH-responsive liposomes of dioleoyl phosphatidylethanolamine and cholesteryl hemisuccinate for the enhanced anticancer efficacy of cisplatin[J]. Pharmaceutics, 2022, 14(1): 129.
[3] Varshosaz J, Taymouri S, Hassanzadeh F, et al. Folated Synperonic‐Cholesteryl Hemisuccinate Polymeric Micelles for the Targeted Delivery of Docetaxel in Melanoma[J]. BioMed research international, 2015, 2015(1): 746093.
[4] Kulig W, Jurkiewicz P, Olżyńska A, et al. Experimental determination and computational interpretation of biophysical properties of lipid bilayers enriched by cholesteryl hemisuccinate[J]. Biochimica et Biophysica Acta (BBA)-Biomembranes, 2015, 1848(2): 422-432.
[5] Sauk J J, Krumwiede M, Cooking‐Johnson D, et al. Alterations in lipid fluidity induced by cholesterol and cholesterol hemisuccinate modulate the organization of microtubule skeletons in epithelial cells[J]. Journal of Oral Pathology & Medicine, 1987, 16(2): 69-74.
[6] Ray S D, Mumaw V R, Raje R R, et al. Protection of acetaminophen-induced hepatocellular apoptosis and necrosis by cholesteryl hemisuccinate[J]. Journal of Pharmacology and Experimental Therapeutics, 1996, 279: 1470-1483.
| 動物実験 [1]: | |
動物モデル | ICRマウス |
準備方法 | アセトアミノフェン（AAP）とCholesteryl Hemisuccinateの両方を生理食塩水に溶解し、腹腔内投与した。Cholesteryl Hemisuccinateを激しく超音波処理し、均一な懸濁液を形成し、pHを7.4に調整した。動物にCholesteryl Hemisuccinate (100mg/kg, i.p.)を投与し、12時間正常食に戻した。次に、動物を12時間断食させ、AAP暴露を受けさせた。AAP投与の2時間後に、動物に飼料と水を自由に摂らせ、AAP暴露の24時間後に、動物を殺処分し、生物化学と形態分析のために、組織（血液と肝臓）を採取した。 |
投与形態 | 100mg/kg; i.p. |
アプリケーション | Cholesteryl Hemisuccinateの事前処理の結果、AAP誘発の肝損傷を阻害し、肝細胞壊死とアポトーシスを抑制した。 |
References: | |
| Cas No. | 1510-21-0 | SDF | |
| 同義語 | Cholesteryl hydrogen succinate | ||
| Canonical SMILES | C[C@]12C(C[C@@H](OC(CCC(O)=O)=O)CC2)=CC[C@]3([H])[C@]1([H])CC[C@@]4(C)[C@@]3([H])CC[C@@]4([C@@H](CCCC(C)C)C)[H] | ||
| Formula | C31H50O4 | M.Wt | 486.7 |
| 溶解度 | Chloroform: 10 mg/ml | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 2.0547 mL | 10.2733 mL | 20.5465 mL |
| 5 mM | 410.9 μL | 2.0547 mL | 4.1093 mL |
| 10 mM | 205.5 μL | 1.0273 mL | 2.0547 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 2 reference(s) in Google Scholar.)